Pasar al contenido principal

PAPEL DE LAS CELULAS T REGULADORAS EN LA REGENERACION DE NERVIOS PERIFERICOS ENVEJECIDOS O CRONICAMENTE DAÑADOS

PID2022-143269OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIÓN DE LA COMUNITAT VALENCIANA PARA LA GESTIÓN DEL INSTITUTO DE INVESTIGACIÓN SANITARIA Y BIOM

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Glial cell alterations in diabetes-induced neurodegeneration

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Senescent Schwann cells induced by aging and chronic denervation impair axonal regeneration following peripheral nerve injury

  • Fuentes-Flores, Andrés
  • Geronimo-Olvera, Cristian
  • Girardi, Karina
  • Necuñir-Ibarra, David
  • Patel, Sandip Kumar
  • Bons, Joanna
  • Wright, Megan C.
  • Geschwind, Daniel
  • Hoke, Ahmet
  • Gómez-Sánchez, José A.
  • Schilling, Birgit
  • Rebolledo, Daniela L.
  • Campisi, Judith
  • Court, Felipe A.
Following peripheral nerve injury, successful axonal growth and functional recovery require Schwann cell (SC) reprogramming into a reparative phenotype, a process dependent upon c-Jun transcription factor activation. Unfortunately, axonal regeneration is greatly impaired in aged organisms and following chronic denervation, which can lead to poor clinical outcomes. While diminished c-Jun expression in SCs has been associated with regenerative failure, it is unclear whether the inability to maintain a repair state is associated with the transition into an axonal growth inhibition phenotype. We here find that reparative SCs transition into a senescent phenotype, characterized by diminished c-Jun expression and secretion of inhibitory factors for axonal regeneration in aging and chronic denervation. In both conditions, the elimination of senescent SCs by systemic senolytic drug treatment or genetic targeting improved nerve regeneration and functional recovery, increased c-Jun expression and decreased nerve inflammation. This work provides the first characterization of senescent SCs and their influence on axonal regeneration in aging and chronic denervation, opening new avenues for enhancing regeneration and functional recovery after peripheral nerve injuries., This work was supported by grants from the Geroscience Center for BrainHealth and Metabolism, Fondo de financiamiento de Centros de Investigacion en Areas Prioritarias (FONDAP) N°15150012, Fondo Nacionalde Desarrollo Cientifico y Tecnologico (FONDECYT) N°1150766and Michael J Fox Foundation for Parkinson’s Research 17303(FAC). Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AH and DHG). National Institutes of Health under award numbers U01AG060906(BS), P01AG017242and R01AG051729(JC). We acknowledge the support of instrumentation for the Orbitrap Eclipse Tribrid from the NCRR shared instrumentation grant 1S10OD028654(BS). SKP is supported by a Glenn Fellowship in Aging Research from the Glenn Foundation. Miguel Servet Fellowship from the Spanish Health Institute Carlos III (CP22/00078) andPlan Nacional2022from the Agencia Estatal de Investigacion (PID2022-143269OB-100) (JAG-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Glial cell alterations in diabetes-induced neurodegeneration

  • Llorián-Salvador, Maria
  • Cabeza-Fernández, Sonia
  • Gómez-Sánchez, José A.
  • Fuente, Alerie G. de la
Type 2 diabetes mellitus is a global epidemic that due to its increasing prevalence worldwide will likely become the most common debilitating health condition. Even if diabetes is primarily a metabolic disorder, it is now well established that key aspects of the pathogenesis of diabetes are associated with nervous system alterations, including deleterious chronic inflammation of neural tissues, referred here as neuroinflammation, along with different detrimental glial cell responses to stress conditions and neurodegenerative features. Moreover, diabetes resembles accelerated aging, further increasing the risk of developing age-linked neurodegenerative disorders. As such, the most common and disabling diabetic comorbidities, namely diabetic retinopathy, peripheral neuropathy, and cognitive decline, are intimately associated with neurodegeneration. As described in aging and other neurological disorders, glial cell alterations such as microglial, astrocyte, and Müller cell increased reactivity and dysfunctionality, myelin loss and Schwann cell alterations have been broadly described in diabetes in both human and animal models, where they are key contributors to chronic noxious inflammation of neural tissues within the PNS and CNS. In this review, we aim to describe in-depth the common and unique aspects underlying glial cell changes observed across the three main diabetic complications, with the goal of uncovering shared glial cells alterations and common pathological mechanisms that will enable the discovery of potential targets to limit neuroinflammation and prevent neurodegeneration in all three diabetic complications. Diabetes and its complications are already a public health concern due to its rapidly increasing incidence, and thus its health and economic impact. Hence, understanding the key role that glial cells play in the pathogenesis underlying peripheral neuropathy, retinopathy, and cognitive decline in diabetes will provide us with novel therapeutic approaches to tackle diabetic-associated neurodegeneration., This work was supported by a Miguel Servet Fellowship from the Spanish Health Institute Carlos III (CP21/00032 to AGF), a grant from the Spanish State Research Agency corresponding to “Plan Nacional 2021” (PID2021-124465OA-I00 to AGF), the Maria Zambrano fellowship from Spanish Ministry of Science, Innovation and Universities, financed by European Union “NextGenerationEU” (Universitat Autònoma de Barcelona, to MLS), a Miguel Servet Fellowship from the Spanish Health Institute Carlos III (CP22/00078 to JAGS), a grant from the Spanish State Research Agency corresponding to “Plan Nacional 2022” (PID2022-143269OB-I00 to JAGS) and a grant from the “X Convocatoria Intramural 2023” from ISABIAL (Modality F to AGF)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Regulatory T cell expansion prevents retinal degeneration in type 2 diabetes

  • Llorián-Salvador, Maria
  • Pérez-Martínez, Daniel
  • Tang, Miao
  • Duarri, Anna
  • García-Ramírez, Marta
  • Deàs-Just, Anna
  • Álvarez-Guaita, Anna
  • Ramos-Pérez, Lorena
  • Bogdanov, Patricia
  • Gómez-Sánchez, José A.
  • Stitt, Alan W.
  • Hernández Pascual, Cristina
  • Fuente, Alerie G. de la
  • Simó, Rafael
[Background] The global incidence of type 2 diabetes (T2D) is rapidly increasing, with retinopathy being its most common complication and a leading cause of preventable blindness. Although the precise mechanisms involved in the development of diabetic retinopathy (DR) are not fully understood, defective immunomodulation is a recognized key factor in its pathophysiology. Regulatory T cells (Treg) regulate inflammation and promote regeneration, and while they are known to have important anti-inflammatory and neuroprotective roles in other tissues, including central nervous system, their role in the diabetic retina remains largely unknown. The aim of the present study is to examine the effect of Treg expansion of retinal neurodegeneration, an early event in the pathogenesis of DR., [Methods] Treg expansion was achieved by co-injecting recombinant mouse IL-2 with anti-IL-2 monoclonal antibody or its isotype in db/db mice as an established model of T2D. Treg expansion was confirmed via flow cytometry in blood, spleen, and retina. Fundus angiography was performed in the days prior to animal sacrifice at 18 weeks. To study the effect of Tregs on retinal neurons, glia and vascular permeability, immunohistochemistry against Cone-Arrestin, PKCα, synaptophysin, ChAT, TH, GFAP, Iba-1, calbindin, Brn3a, RBPMS, isolectin B4, and albumin was used. Retinal VEGF levels were measured with a magnetic bead-based immunoassay, and NLRP3, Casp1, p20 and IL-18 were analyzed by Western Blot in retinal homogenates., [Results] There was a significant decrease in Treg in db/db mice blood. When this deficiency was corrected in db/db mice by systemic Treg expansion, there was an effective protection against retinal neurodegenerative, gliotic, inflammatory changes and vascular leakage associated with T2D. Importantly, Treg expansion did not impact the T2D phenotype in db/db mice as evaluated by blood glucose, HbA1c and circulating insulin., [Conclusion] Treg modulation in T2D offers a promising therapeutic approach to prevent early stages of DR. This strategy focuses on reducing neuroinflammation and mitigating the associated neuronal, glial, and vascular degenerative changes characteristic of DR., This work has been partially supported by Col·legi Oficial de Farmacèutics de Barcelona. M.L.S.: Maria Zambrano fellowship from Spanish Ministry of Science, Innovation and Universities, financed by European Union “NextGenerationEU” (Universitat Autònoma de Barcelona), and Beatriu de Pinos fellowship, financed by Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, Generalitat de Catalunya). AGF research is supported by a Miguel Servet Fellowship from the Spanish Health Institute Carlos III (CP21/00032) and a grant from the Spanish State Research Agency corresponding to “Proyectos de Generación del Conocimiento 2021” (PID2021-124465OA-I00 funded by MICIU/AEI/13.13039/501100011033/ERDF, EU). JAGS research is supported by a Miguel Servet Fellowship from the Spanish Health Institute Carlos III (CP22/00078) and a grant from the Spanish State Research Agency corresponding to “Proyectos de Generación del Conocimiento 2022” (PID2022- 143269OB-I00)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Schwann cells in regeneration and cancer: an epithelial-mesenchymal transition perspective

  • Graciá Quiles, Francisco
  • Sánchez-Laorden, Berta
  • Gómez-Sánchez, José A.
In the peripheral nervous system, glial cells, known as Schwann cells (SCs), are responsible for supporting and maintaining nerves. One of the most important characteristics of SCs is their remarkable plasticity. In various injury contexts, SCs undergo a reprogramming process that generates specialized cells to promote tissue regeneration and repair. However, in pathological conditions, this same plasticity and regenerative potential can be hijacked. Different studies highlight the activation of the epithelial-mesenchymal transition (EMT) as a driver of SC phenotypic plasticity. Although SCs are not epithelial, their neural crest origin makes EMT activation crucial for their ability to adopt repair phenotypes, mirroring the plasticity observed during development. These adaptive processes are essential for regeneration. However, EMT activation in SCs-derived tumours enhances cancer progression and aggressiveness. Furthermore, in the tumour microenvironment (TME), SCs also acquire activated phenotypes that contribute to tumour migration and invasion by activating EMT in cancer cells. In this review, we will discuss how EMT impacts SC plasticity and function from development and tissue regeneration to pathological conditions, such as cancer., This work was supported by a Miguel Servet Fellowship from the Spanish Health Institute Carlos III (CP22/00078 to J.A.G.-S.) and by the Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación, MCIN/AEI/10.13039/501100011033 and ERDF (PID2019-106852-RBI00 and PID2022-141613OB-I00 to B.S.-L. and PID2022-143269OB-I00 to J.A.G.-S.). We also acknowledge financial support from ISABIAL through a grant from Convocatoria Intramural 2024, the GVA through the ‘Prometeo Programme’ for Groups of Excellence (CIPROM/2021/045) and International Center for Ageing Research (ICAR) to B.S.-L., and Centro de Excelencia Severo Ochoa, grant CEX2021-001165-S, funded by MCIN/AEI/10.13039/501100011033. Illustrations were created with BioRender., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

HDAC11 deficiency regulates age-related muscle decline and sarcopenia

  • Odria, Renato
  • Cardús, Aina
  • Gomis-Coloma, Clara
  • Balanyà-Segura, Marta
  • Mercado-Amarilla, Alexandra
  • Maestre-Mora, Pau
  • Poveda-Sabuco, Andrea
  • Domingo, Joan Carles
  • Nogales-Gadea, Gisela
  • Gómez-Sánchez, José A.
  • Hurtado, Erica
  • Suelves, Mònica
Sarcopenia, defined as the progressive loss of skeletal muscle mass and function associated with ageing, has devastating effects in terms of reducing the quality of life of older people. Muscle ageing is characterised by muscle atrophy and decreased capacity for muscle repair, including a reduction in the muscle stem cell pool that impedes recovery after injury. Histone deacetylase 11 (HDAC11) is the newest member of the HDAC family and it is highly expressed in skeletal muscle. Our group recently showed that genetic deficiency in HDAC11 increases skeletal muscle regeneration, mitochondrial function and globally improves muscle performance in young mice. Here, we explore for the first time the functional consequences of HDAC11 deficiency in old mice, in homeostasis and during muscle regeneration. Aged mice lacking HDAC11 show attenuated muscle atrophy and postsynaptic fragmentation of the neuromuscular junction, but no significant differences in the number or diameter of myelinated axons of peripheral nerves. Maintenance of the muscle stem cell reservoir and advanced skeletal muscle regeneration after injury are also observed. HDAC11 depletion enhances mitochondrial fatty acid oxidation and attenuates age-associated alterations in skeletal muscle fatty acid composition, reducing drastically the omega-6/omega-3 fatty acid ratio and improving significantly the omega-3 index, providing an explanation for improved muscle strength and fatigue resistance and decreased mortality. Taken together, our results point to HDAC11 as a new target for the treatment of sarcopenia. Importantly, selective HDAC11 inhibitors have recently been developed that could offer a new therapeutic approach to slow the ageing process., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by Ministerio de Economía y Competitividad (BFU2016-80748 to M.S.), Ministerio de Ciencia, Innovación y Universidades (PID2020-118730RB-I00 to M.S. and PID2022-143269OB-I00 to J.A.G-S.), Instituto de Salud Carlos III (PI22/00104 to G.N-G.) and Feder funds. R.O. was supported in part by AFM 23557 project; A.M-A. was supported by the BECAL National Programme of Scholarships Abroad Don Carlos Antonio López; P.M-M. was supported by the Programa Investigo 2022 INV-1 00008 (Generalitat de Catalunya); J.A.G-S. and G.N-G. were supported by a Miguel Servet Fellowship from the Instituto de Salud Carlos III (CP22/00078 and CPII19/00021, respectively) and E.H. was partially supported by BFU2016-80748., Peer reviewed